Release date: May 22, 2019
Expiration date: May 21, 2020
Physicians – Maximum of 1.0 AMA PRA Category 1 Credits™
Registered Nurses – 1.0 contact hours (0.7 pharmacotherapy)
Target Audience
The target audience for this activity is U.S.-based hematologists/oncologists, advanced practice nurses, physician assistants, oncology nurses, nurse navigators, and cancer center administrators caring for patients with non-Hodgkin lymphoma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Evaluate clinical trial data regarding the efficacy and safety of approved therapies for the treatment of FL and DLBCL
- Apply evidence-based guidelines to the choice of optimal FL and DLBCL treatment
- Evaluate evidence regarding the efficacy and safety of emerging therapies for the treatment of FL and DLBCL in clinical trials
- Apply shared decision-making practices, tools, and resources into clinical care for patients with FL and DLBCL
Educational Phases
Phase 1 Activate
- Update on emerging treatments for DLBCL and FL
- But I already do Shared-Decision Making! How is this going to be different?
Phase 2 Advance
- Case vignette/roleplay: Integrating patient preferences/goals into an SDM encounter
- Case vignette/roleplay: Integrating prognosis/goals of care discussions into an SDM encounter
Phase 3 Lessons Learned
- Applying a shared decision-making framework for treatment planning in diffuse large B-cell lymphoma and follicular lymphoma
- A case study of the first 10 patients
Faculty
Amitkumar Mehta, MD
University of Alabama at Birmingham
Arif Kamal, MD
Duke University School of Medicine
Amy Goodrich, MSN, RN, CRNP-AC
Johns Hopkins Kimmel Cancer Center
Debra Wujcik, PhD, RN, FAAN
Carevive Systems, Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Medical Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Amitkumar Mehta, MD
Consulting Fees: Astrazeneca, Celgene, Gilead, Kite
Contracted Research: Bristol Myers-Squibb, Epizyme, Incyte, Merck, Roche
Arif Kamal, MD
Salary: Acclivity Health
Ownership Interest less than 5%: Acclivity Health
Ownership Interest greater than 5%: Prepped Health
Amy Goodrich, MSN, RN, CRNP-AC
Consulting Fees: Gilead, Sandoz, Mylan
Debra Wujcik, PhD, RN, FAAN
No real or apparent conflicts of interest to report.
The PIM planners and managers have nothing to disclose. The Carevive Systems, Inc. planners and managers have nothing to disclose.
Media
PowerPoint With Voiceover, Animated Video
Fee Information
There is no fee for this educational activity.
Instructions for Obtaining Credit
During the period May 22, 2019, through May 21, 2020, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-survey/evaluation. If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 12766. Once completed, your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.
Computer System Requirements
CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc. Grant funding provided by Genentech, Inc.
